Literature DB >> 19995647

Differential expression of biomarkers in men and women.

David Planchard1, Yohann Loriot, Aicha Goubar, Fréderic Commo, Jean-Charles Soria.   

Abstract

Lung cancer is one of the most common cancers in the world. While historically, more men than women have died from lung cancer as a result of higher numbers of male smokers, the sex mortality ratio is now showing signs of narrowing. Tumors in women with lung cancer may be slightly different to those in men with lung cancer. This review focuses on biomarkers differentially expressed between female and male patients with lung cancer. There is variation in gene expression between men and women in some genes that encode carcinogen-metabolizing enzymes (CYP1A1, GSTM). Gastrin-releasing peptide (GRP), a bombesin-like peptide, is present in two actively transcribed alleles in women compared with men. Higher prevalence of infection with oncogenic variants human papilloma viruses (HPVs) HPV16 and HPV18 has been suggested in women. A higher frequency of G to T transversion was found in the p53 gene in lung tumors of women. KRAS mutation was found to be more frequent in women with resected non-small cell lung cancer (NSCLC) than in men with resected NSCLC. Epidermal growth factor receptor (EGFR) mutation is more frequently found in lung tumors from women, but the confounding effect of tobacco exposure may explain this difference. Lower levels of ERCC1 and BRCA1 have been reported in women with NSCLC. Lung tumors from women are more likely to express estrogen receptors than those from men. An in silico analysis of transcriptome datasets from lung cancer patients demonstrated that only seven genes (in at least two studies) had significantly different expression patterns in male versus female patients. All of these genes are localized on the sex chromosomes: one on chromosome X and six on chromosome Y. Many areas remain under debate and there are still significant gaps in our understanding, particularly how sex-linked factors relate to lung cancer risk, and to biological and clinical behaviors. Future research into lung cancer needs to address these gender differences more specifically.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19995647     DOI: 10.1053/j.seminoncol.2009.09.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  22 in total

1.  Tangeretin and its metabolite 4'-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K.

Authors:  Z Cheng; S Surichan; K Ruparelia; R Arroo; M R Boarder
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

2.  Sex disparities in cancer mortality and survival.

Authors:  Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

Review 3.  Mendelian randomization: potential use of genetics to enable causal inferences regarding HIV-associated biomarkers and outcomes.

Authors:  Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

4.  Gastric cancer drug trials - are women second class citizens?

Authors:  Lishi Wang; Yan Jiao; Yun Jiao; Yanhong Cao; Weikuan Gu
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

Review 5.  Lung cancer in women.

Authors:  Raúl Barrera-Rodriguez; Jorge Morales-Fuentes
Journal:  Lung Cancer (Auckl)       Date:  2012-12-15

Review 6.  The epidemiology of lung cancer.

Authors:  Patricia M de Groot; Carol C Wu; Brett W Carter; Reginald F Munden
Journal:  Transl Lung Cancer Res       Date:  2018-06

7.  How close are we to customizing chemotherapy in early non-small cell lung cancer?

Authors:  Georgios Ioannidis; Vassilis Georgoulias; John Souglakos
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

8.  Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort.

Authors:  Marshall W Pitz; Grace Musto; Srisala Navaratnam
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

9.  Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women.

Authors:  Emanuela Anastasi; Teresa Granato; Giulia Giovanna Marchei; Valentina Viggiani; Barbara Colaprisca; Sara Comploj; Maria Gabriella Reale; Luigi Frati; Cecilia Midulla
Journal:  Tumour Biol       Date:  2010-05-20

Review 10.  Sexual dimorphism in solid and hematological malignancies.

Authors:  Isabel Ben-Batalla; María Elena Vargas-Delgado; Lara Meier; Sonja Loges
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.